MRI data collected on the patients in the open-label dose-escalation study revealed that those patients who would be included in the Phase II clinical study, by virtue of dose and tissue type compatibility, show an increase in ejection fraction by 5.2% and a relative reduction in scar size of 20.7% at 12-month follow-up. The presentation highlighted that intracoronary infusion of allogeneic cardiosphere-derived cells appears to be safe and on track for demonstrating efficacy.
http://ift.tt/XLColz
http://ift.tt/XLColz
No comments:
Post a Comment